← Back to Search

Digital Intervention for Smoking Cessation in Mental Illness

N/A

Waitlist Available

Research Sponsored by University of Maryland, Baltimore

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 or greater

Current smoker [prior to admission, smoked at least one cigarette or small cigar per day in the past month (unless restricted, e.g. due to ER/hospital visit) and smoked at least 100 cigarettes lifetime]

Must not have

Medical condition for which the use of nicotine replacement therapy (NRT) is contraindicated including pregnant, planning to become pregnant, or breastfeeding; within 4 weeks post myocardial infarction; severe arrhythmia, severe angina pectoris; peptic ulcer; severe renal failure; poorly controlled insulin-dependent diabetes; severely uncontrolled hypertension; peripheral vascular disease.

Discharge to a residential setting where smoking is prohibited

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will test whether a digital intervention can help people with serious mental illness quit smoking after they leave the hospital.

Who is the study for?

This trial is for adults over 18 with serious mental illnesses like schizophrenia, bipolar disorder, or major depression who smoke and want to quit after hospital discharge. They should be able to read, use the internet regularly post-discharge, have a mobile device with texting capability, and live within an hour of the hospital.

What is being tested?

The study tests a digital smoking cessation program called BecomeAnEX designed for people with serious mental illness. It's compared against usual care methods. The goal is to help patients stay smoke-free after leaving the psychiatric hospital by using this adapted online tool.

What are the potential side effects?

Since this intervention involves a digital platform rather than medication, typical drug side effects are not expected. However, participants may experience stress or frustration if they encounter difficulties using the technology or while trying to quit smoking.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I currently smoke at least one cigarette a day and have smoked 100 in my lifetime.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I cannot use nicotine replacement therapy due to a serious health condition or pregnancy.

Select...

I will be discharged to a smoke-free home.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Acceptability

Craving

Feasibility of recruitment

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: BecomeAnEXExperimental Treatment2 Interventions

Participants will have three individual meetings with a research staff person while they are in the hospital. At these meetings participants will answer questions about their smoking and interest in quitting, learn about BecomeAnEx, and register with the BecomeAnEx program so that they can use it when you leave the hospital. Participants will be given two weeks of nicotine replacement therapy when they leave the hospital. Participants will be asked to use BecomeAnEx as much as they want when they leave the hospital.

Group II: Usual CareActive Control1 Intervention

Brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Usual Care

1990

Completed Phase 4

~7700

0 / 4Eligibility criteria met